Metagenomi Reports Q1 2026 Financials: Collaboration Revenue Plummets 70%, Key Partnership Modified
Summary
Metagenomi Therapeutics reported a sharp decline in Q1 collaboration revenue and a significant modification to its Ionis partnership, signaling headwinds despite a stable cash runway.
Key Events
-
Collaboration Revenue Plummets
Collaboration revenue decreased by 70% year-over-year to $1.2 million in Q1 2026, down from $4.1 million in Q1 2025.
-
Ionis Collaboration Modified
The drug discovery plan for one Wave 1 target was modified, leading to additional costs and extended timing. The exploratory research plan was discontinued, with a potential one-time non-cash revenue reversal expected in Q2 2026.
-
Cash Runway Confirmed
The company expects its existing cash, cash equivalents, and marketable securities of $140.2 million as of March 31, 2026, to fund operations for at least the next 12 months from the filing date.
-
Ongoing Securities Litigation
A class action lawsuit alleging misleading statements regarding the Moderna collaboration continues, with the court having partially denied the defendants' motion to dismiss on March 24, 2026.
Analysis
Metagenomi Therapeutics' Q1 2026 results reveal a significant 70% year-over-year decline in collaboration revenue, a critical metric for this pre-revenue biotech. The modification of the Ionis collaboration, including the discontinuation of exploratory research and a potential revenue reversal, raises concerns about future pipeline development and revenue streams. While the company maintains a 12-month cash runway, the substantial revenue drop and ongoing securities litigation present considerable challenges.
At the time of this filing, MGX was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $1.25 to $3.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.